Beyond The Printed Page

  1. 3 Questions With Regeneron’s Chief Scientific Officer — George Yancopoulos

    George Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron Pharmaceuticals, discusses failure, finding top talent, and thoughts on retirement.  

  2. What Transformative Technologies Are Biopharma Manufacturing Leaders Watching?

    Five biopharma manufacturing leaders share their thoughts on the disruptive technologies with the potential to transform biopharmaceutical industry manufacturing.

  3. Preparing For JPM As A Small Private Company

    Michael Bonney shares what it was like to prepare (somewhat last minute) and present at the annual J.P. Morgan Healthcare Conference (JPM) as the CEO of Kaleido Biosciences, a small privately-held biopharmaceutical company. In addition, he compares this to previous experiences of presenting at JPM as the CEO of a larger publically traded biopharma.

  4. Michael Bonney On How Biogen And Cubist Differ From Kaleido Biosciences

    Michael Bonney, CEO of Kaleido Biosciences, discusses some of the differences between his past and present employers.

  5. Achieving Leadership Diversity Isn’t Easy

    Michael Bonney, CEO of Kaleido Biosciences, discusses some of the challenges faced — and how to overcome those — when building a diverse leadership team.

  6. 4 Questions With John Maraganore, CEO Of Alnylam Pharmaceuticals

    John Maraganore, CEO of Alnylam Pharmaceuticals and current chair for BIO, shares thoughts on CROs, open science, and his company’s future.

  7. What Are Sugar-Engineered Antibodies?

    The CEO and founder of Seattle Genetics, Clay Siegall, discusses one of the company’s new technologies, sugar-engineered antibodies (SEAs).

  8. How Seattle Genetics Got Bill Gates And Paul Allen As Investors

    The founder and CEO of Seattle Genetics discusses a number of interesting topics, including how he was able to get the founders of Microsoft as early investors in his company.

  9. The Story Behind Seattle Genetics’ Unintentional-Startup Incubator

    Clay Siegall, the founder of Seattle Genetics, explains how his company became an unintentional-startup incubator for Alder BioPharmaceuticals.

  10. Seattle Genetics Legacy Of Partnering

    The CEO of Seattle Genetics discusses the past, present, and future of some of his company’s partnerships.